Zocaglusagene nuzaparvovec

NEW YORK, March 18, 2024 /PRNewswire/ -- Technavio categorizes the global gene therapy market size as estimated to increase by USD 4,613.9 million between 2022 and 2027. The market's growth momentum will be progressing at a CAGR of 19.91% during the forecast period. During the forecast period, North America is anticipated to drive 39% of global market growth, as per Technavio's analysts. The US, particularly, emerges as a promising investment hub within the region, supported by substantial funding from entities like the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) to emerging players in the market. This influx of government and private sector investment is propelling the development of innovative gene therapies, with 18 clinical trials and 17 biotech startups underway. Such financial backing is poised to significantly stimulate market demand in the coming years. Continue Reading Technavio has announced its latest market research report titled Global Gene Therapy Market 2023-2027 Discover some insights on market size historic data (2017 to 2021) and Forecast (2023 to 2027) before buying the full report - Request a sample report Technavio has segmented the market based on therapy areas (oncology, CNS, ophthalmology, rare diseases, and others), and delivery mode (in vivo and ex vivo). The market growth in the oncology segment will be significant during the forecast period. The global oncology drugs market has a huge unmet demand for the treatment of various indications. Also, the increasing prevalence of cancer indications has led pharmaceutical companies and research institutions to conduct extensive research to develop drugs for these indications. The lack of efficacy of small molecules and biomolecules has led companies to move towards effective therapeutic options such as gene therapy. Such factors will increase the segment growth during the forecast period. For insights on global, regional, and country-level parameters with growth opportunities from 2017 to 2027 - Download a Sample Report Key Companies The global gene therapy market is fragmented, with the presence of several global as well as regional vendors. A few prominent vendors that offer gene therapy in the market are Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., bluebird bio Inc., Editas Medicine Inc., ElevateBio, F. Hoffmann La Roche Ltd., Generation Bio Co., Gilead Sciences Inc., Novartis AG, Orchard Therapeutics Plc, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Sibiono GeneTech Co. Ltd., Syncona Ltd., uniQure NV, and Voyager Therapeutics Inc. and others. Abeona Therapeutics Inc.: The company offers gene therapy solutions such as Phase 3 VIITAL Clinical Trial of EB 101. Amgen Inc.: The company offers gene therapy solutions such as CAR T cell immunotherapies. Astellas Pharma Inc.: The company offers gene therapy solutions such as AT132, AT845, AT466. Biogen Inc.: The company offers gene therapy solutions such as GTxAU. The growth of the market is driven by the increase in special drug designations. Most gene therapy programs have been granted orphan drug designation, fast track designation, or breakthrough designation by the U.S. FDA, EMA, and other regulatory bodies for the treatment of certain diseases. In addition, orphan drug status will also help the company with tax incentives in its next research. Such advantages of specialty drug designations will drive the growth of the market during the forecast period. Growing research in gene therapy for CVDs and orphan diseases is one of the key market trends that is contributing to the market growth. High treatment cost is one of the factors hindering the gene therapy market growth. Driver, Trend & Challenges are the factor of market dynamics which states about consequences & sustainability of the businesses, find some insights from a sample report! Analyst Review Gene therapy stands at the forefront of medical innovation, offering promising solutions for a myriad of genetic disorders ranging from atrophy to muscular dystrophy. As the world grapples with health challenges like the COVID-19 pandemic, companies like Applied Genetic Technologies Corporation and Benitec Biopharma in countries like Australia and Belgium are actively engaged in pioneering gene therapy research to combat such conditions. Beta thalassemia, sickle cell disease, and spinal muscular atrophy represent just a fraction of the genetic issues that gene therapy aims to address. With the advent of breakthrough treatments like betibeglogene autotemcel and onasemnogene abeparvovec, patients suffering from these debilitating conditions now have newfound hope. The gene therapy market, bolstered by advancements in CRISPR Therapeutics and lentivirus technology, is witnessing exponential growth. As companies like Pfizer, Cellectis, and Novartis Gene Therapies invest in research and development, the market is projected to expand further, especially in regions like California and Massachusetts, known for their biotechnology hubs. However, this growth isn't without challenges. Regulatory bodies like ClinicalTrials.gov, the FDA, and the International Organization for Standardization (ISO 9000) play pivotal roles in ensuring the safety and efficacy of gene therapies. Striking a balance between innovation and compliance with regulations such as the California Consumer Privacy Act and the General Data Protection Regulation remains paramount. One of the critical factors driving the gene therapy market is the increasing prevalence of genetic disorders worldwide. From hereditary illnesses to congenital diseases, the demand for innovative treatments continues to rise. Moreover, with advancements in gene editing and therapeutic gene delivery systems, the potential to target specific cells and protein molecules offers new avenues for treatment. Venture capital financing and partnerships between academia and industry players further fuel research efforts. Companies like Lonza Group and Oxford Biomedica contribute to the manufacturing and logistics aspects of gene therapy, ensuring efficient drug delivery and scalability. In conclusion, the gene therapy market holds immense promise in addressing genetic disorders and improving patient outcomes. As the field continues to evolve, collaboration, adherence to regulations, and a focus on patient-centric approaches will be essential in unlocking the full potential of gene therapy to tackle the most challenging medical conditions of our time. Download a Sample Report Market Overview The Gene Therapy Market is witnessing exponential growth globally, with companies like Applied Genetic Technologies Corporation and Benitec Biopharma leading the charge. This revolutionary approach offers hope for conditions such as atrophy and beta thalassemia, providing targeted solutions to genetic disorders. Recent advancements include Betibeglogene autotemcel, a promising treatment for beta-thalassemia pioneered by CRISPR Therapeutics. Biomedicine is at the forefront of this transformative field, driving innovation and clinical trials. Amidst the COVID-19 pandemic, gene therapy research continues unabated, with countries like Australia and Belgium actively contributing to the global effort. As the market expands, gene therapy emerges as a beacon of hope for patients worldwide, offering personalized treatments and potential cures. Download a Sample Report Related Reports: The cell and gene therapy market size is expected to increase by USD 9.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 20.15%. The cell therapy market size is expected to increase by USD 21.061 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 56.79%. TOC Executive Summary Market Landscape Market Sizing Historic Market Size Five Forces Analysis Market Segmentation by Therapy Areas market Segmentation by Delivery Mode Customer Landscape Geographic Landscape Drivers, Challenges, and Trends Company Landscape Company Analysis Appendix About US Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

The latest around the BIOSECURE Act, Takeda's plan to shut down a gene therapy facility, and an early death issue in Carvykti's clinical trial made our news this week. WuXi AppTec left the Biotechnology Industry Organization amid increasing pressure on the trade group stemming from a draft U.S. bill targeting certain Chinese biotechs. Takeda will shut down a facility in Austria as the Japanese pharma pivots away from research in adeno-associated virus gene therapies. The FDA questioned whether Carvykti should be approved in earlier multiple myeloma after noticing an early detriment to patients' survival in a clinical trial. And more. 1. Biotech trade group pledges support for BIOSECURE Act, plans to boot member WuXi AppTec The Biotechnology Industry Organization (BIO) is severing ties with WuXi AppTec as one of the “important steps” that the trade group is taking to support U.S. national security. In a revised statement, BIO said WuXi “proactively ended its membership.” BIO said it supports the BIOSECURE Act, which looks to block “adversary biotech companies,” including WuXi, from getting U.S. government contracts. BIO’s move came after its lobbying activity against the draft bill drew the ire of a lawmaker. 2. Takeda winds down manufacturing and R&D operations in Austria after gene therapy pivot, plots 190 layoffs Takeda is shutting down operations at its adeno-associated virus gene therapy plant in Orth, Austria, and nearly 200 employees will lose their jobs. Takeda said it would divest the site about a year ago as part of its decision to end early R&D activities around AAV gene therapies. But after a “thorough and lengthy effort,” the company couldn’t find a buyer, a Takeda spokesperson said. 3. FDA flags early deaths in CAR-T myeloma trials for J&J and Legend’s Carvykti, Bristol Myers’ Abecma The FDA has raised concerns about an increased risk of death for Johnson & Johnson and Legend Biotech’s Carvykti compared with standard combinations in the first few months of its phase 3 trial in earlier lines of treatment for multiple myeloma. More patients in the Carvykti arm died than those in the control arm in the first 10 months of the CARTITUDE-4 trial. That overall survival data set is up for discussion during an FDA advisory committee meeting. 4. Astellas puts the cork back in $350M Xork deal after Cartesian-Selecta merger Astellas has decided to end a licensing deal with Cartesian Therapeutics about a year after signing it originally with Selecta Biosciences. Under the deal, Astellas paid $10 million upfront to use Cartesian’s Xork, an immunoglobulin protease, with its gene therapy candidate AT845. The hope was that the asset would help more patients become eligible for adeno-associated virus-based gene therapies. 5. Insilico 'pulls back the curtain' on AI drug discovery process in hope of convincing skeptics In a Nature Biotechnology paper, Insilico Medicine described how it used artificial intelligence to discover, develop and test its lead candidate, INS018_055, a TNIK inhibitor that’s in phase 2 development for the lung disease idiopathic pulmonary fibrosis. The company’s AI platform, PandaOmics, was used to both identify a therapeutic target and to design a drug candidate. 6. Biocon continues to divest with $150M sale of insulin and other brands to Eris Biocon has agreed to sell its Indian branded formulations business to Eris for about $150 million. The deal includes a portfolio of metabolic, oncology and critical care products, including Insugen, which was the first recombinant human insulin product developed domestically in India. The divested franchise accounted for 3.7% of Biocon’s revenue in its fiscal year 2023. 7. Innovent shutters ADC-focused Maryland R&D site, moves lab to California (BioSpace, Yicai) Innovent Biologics will shut down its Rockville, Maryland, site, which serves as the Chinese firm’s U.S. headquarters and is conducting research in antibody-drug conjugates. A BioSpace article, citing former employees, reported that the R&D work will move to Chin and that the company has axed the entire research team at the Maryland location. But Innovent told Yicai that the lab will be relocated to California. Other News of Note: 8. Chinese authorities rumored to be working on policies to support innovative drugs (Bloomberg) 9. Aurobindo unit begins shipping drugs from India plant after FDA inspection triggered production halt 10. BeiGene bumps AbbVie, J&J from top lymphoma event sponsor spot 11. Sun Pharma issues recall of gout drug due to microbial contamination 12. AstraZeneca taps Mankind to distribute Symbicort in India (The Economic Times)